Pulmonary arterial hypertension in congenital heart disease

Pulmonary Hypertension

Volumn , Issue , 2009, Pages 176-195

  Levi, Daniel S ^a   Scott, Victoria ^b   Aboulhosn, Jamil ^b  

^a MATTEL CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650380505     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (78)

1. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39:1890-1900.
2. Schulze-Neick I, Gilbert N, Ewert R, et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J 2005; 150:716.
3. Wren C, O'Sullivan JJ. Survival with congenital heart disease and need for follow up in adult life. Heart 2001; 85:438-143.
4. Hoffman JI, Christianson R. Congenital heart disease in a cohort of 19,502 births with long-term follow-up. Am J Cardiol 1978; 42:641-647.
5. Bialkowski J, Szkutnik M. Percutaneous closure of patent ductus arteriosus at high altitude. Congenit Cardiol Today 2007; 5:1-2.
6. Warnes CA, Liberthson R, Danielson GK, et al. Task force 1: the changing profile of congenital heart disease in adult life. J Am Coll Cardiol 2001; 37:1170-1175.
7. Hoffman JI, Kaplan S, Liberthson RR. Prevalence of congenital heart disease. Am Heart J 2004; 147:425-139.
8. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351:1425-1436.
9. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25:2243-2278.
10. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173:1023-1030.
11. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114:48-54.
12. Engelfriet P, Meijboom F, Boersma E, et al. Repaired and open atrial septal defects type II in adulthood: an epidemiological study of a large European cohort. Int J Cardiol 2008; 126:379-385.
13. Kidd L, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 1993; 87:138-151.
14. Horvath KA, Burke RP, Collins JJ Jr, et al. Surgical treatment of adult atrial septal defect: early and long-term results. J Am Coll Cardiol 1992; 20:1156-1159.
15. Newfeld EA, Paul MM, Muster AJ, et al. Pulmonary vascular disease in complete transposition of the great arteries: a study of 200 patients. Am J Cardiol 1974; 34:75-82.
16. Tullow R. Congenital heart disease in relation to pulmonary hypertension in paediatric practice. Paediatr Respir Rev 2005; 6:174-180.
17. Beghetti M, Black SM, Fineman JR. Endothelin-1 in congenital heart disease. Pediatr Res 2005; 57:16R-20R.
18. Haworth SG. Pulmonary hypertension in the young. Heart 2002; 88:658-664.
19. Tulloh RM. Congenital heart disease in relation to pulmonary hypertension in paediatric practice. Paediatr Respir Rev 2005; 6:174-180.
20. Rabinovitch M. Elastase and the pathobiology of unexplained pulmonary hypertension. Chest 1998; 114:213S-224S.
21. Diller GP, van Eijl S, Okonko DO, et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 2008; 117:3020-3030.
22. Zhao YD, Courtman DW, Deng Y, et al. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005; 96:442-150.
23. Haworth SG. Pulmonary endothelium in the perinatal period. Pharmacol Rep 2006; 58(suppl):153-164.
24. Wojciak-Stothard B, Haworth SG. Perinatal changes in pulmonary vascular endothelial function. Pharmacol Ther 2006; 109:78-91.
25. Newman JH, Fanburg BL, Archer SL, et al. Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 2004; 109:2947-2952.
26. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732-1739.
27. Black SM, Bekker JM, Johengen MJ, et al. Altered regulation of the ET-1 cascade in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res 2000; 47:97-106.
28. Black SM, Mata-Greenwood E, Dettman RW, et al. Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation 2003; 108:1646-1654.
29. Ovadia B, Reinhartz O, Fitzgerald R, et al. Alterations in ET-1, not nitric oxide, in 1-week-old lambs with increased pulmonary blood flow. Am J Physiol Heart Circ Physiol 2003; 284: H480-H490.
30. Shafique T, Johnson RG, Dai HB, et al. Altered pulmonary microvascular reactivity after total cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 106:479-486.
31. Carteaux JP, Roux S, Siaghy M, et al. Acute pulmonary hypertension after cardiopulmonary bypass in pig: the role of endogenous endothelin. Eur J Cardiothorac Surg 1999; 15:346-352.
32. Komai H, Adatia IT, Elliott MJ, et al. Increased plasma levels of endothelin-1 after car-diopulmonary bypass in patients with pulmonary hypertension and congenital heart disease. J Thorac Cardiovasc Surg 1993; 106:473-478.
33. Perloff JK. The Clinical Recognition of Congenital Heart Disease. 5th ed. Philadelphia: W.B. Saunders Co., 2003.
34. Lock JE, Keane JF, Stanton BP. Diagnostic and Interventional Catheterization in Congenital Heart Disease. 2nd ed. Norwell: Kluwer Academic Publishers, 2000.
35. Lindberg L, Olsson AK, Jogi P, et al. How common is severe pulmonary hypertension after pediatric cardiac surgery? J Thorac Cardiovasc Surg 2002; 123:1155-1163.
36. Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 2005; 112:828-835.
37. Dimopoulos K, Okonko DO, Diller GP, et al. Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival. Circulation 2006; 113:2796-2802.
38. Niwa K, Perloff JK, Kaplan S, et al. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol 1999; 34:223-232.
39. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. J Am Dent Assoc 2007; 138:739-745, 47-60.
40. Fyfe A, Perloff JK, Niwa K, et al. Cyanotic congenital heart disease and coronary artery atherogenesis. Am J Cardiol 2005; 96:283-290.
41. Chugh R, Perloff JK, Fishbein M, et al. Extramural coronary arteries in adults with cyanotic congenital heart disease. Am J Cardiol 2004; 94:1355-1357.
42. Perloff JK. The coronary circulation in cyanotic congenital heart disease. Int J Cardiol 2004; 97(suppl 1):79-86.
43. Dedkov EI, Perloff JK, Tomanek RJ, et al. The coronary microcirculation in cyanotic congenital heart disease. Circulation 2006; 114:196-200.
44. Rosove MH, Perloff JK, Hocking WG, et al. Chronic hypoxaemia and decompensated erythrocytosis in cyanotic congenital heart disease. Lancet 1986; 2:313-315.
45. Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol 1996; 28:768-772.
46. Aboulhosn J, Castellon YM, Shao E, et al. Quantification of pulmonary artery calcium deposits in patients with pulmonary hypertension using computed tomography. In: American Foundation for Medical Research Western Convention, 2005.
47. Silversides CK, Granton JT, Konen E, et al. Pulmonary thrombosis in adults with Eisen-menger syndrome. J Am Coll Cardiol 2003; 42:1982-1987.
48. Perloff JK, Rosove MH, Child JS, et al. Adults with cyanotic congenital heart disease: hematologic management. Ann Intern Med 1988; 109:406-413.
49. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998; 19:1845-1855.
50. Gatzoulis MA, Beghetti M, Galie N, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 2008; 127:27-32.
51. Apostolopoulou SC, Manginas A, Cokkinos DV, et al. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart 2007; 93:350-354.
52. Schulze-Neick I, Hartenstein P, Li J, et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 2003; 108(suppl 1,2):167-173.
53. Okyay K, Cemri M, Boyac B, et al. Use of long-term combined therapy with inhaled iloprost and oral sildenafil in an adult patient with Eisenmenger syndrome. Cardiol Rev 2005; 13:312-314.
54. Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 2006; 114:1807-1810.
55. Lunze K, Gilbert N, Mebus S, et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J Clin Invest 2006; 36(suppl 3):32-38.
56. Ivy DD, Doran AK, Smith KJ, et al. Short-and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51:161-169.
57. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99:1858-1865.
58. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:800-804.
59. Rimensberger PC, Spahr-Schopfer I, Berner M, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 2001; 103:544-548.
60. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41:2119-2125.
61. Finer NN, Etches PC, Kamstra B, et al. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response. J Pediatr 1994; 124:302-308.
62. Tworetzky W, Bristow J, Moore P, et al. Inhaled nitric oxide in neonates with persistent pulmonary hypertension. Lancet 2001; 357:118-120.
63. Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics 1998; 101:325-334.
64. Wessel DL, Adatia I, Thompson JE, et al. Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension. Crit Care Med 1994; 22:930-938.
65. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000; 342:469-174.
66. Roberts JD Jr, Fineman JR, Morin FC III, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997; 336:605-610.
67. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997; 336:597-604.
68. Abman SH, Griebel JL, Parker DK, et al. Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure. J Pediatr 1994; 124:881-888.
69. Kinsella JP, Abman SH. Clinical approach to inhaled nitric oxide therapy in the newborn with hypoxemia. J Pediatr 2000; 136:717-726.
70. Davidson D, Barefield ES, Kattwinkel J, et al. Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn. Pediatrics 1999; 104:231-236.
71. Kerstein D, Levy PS, Hsu DT, et al. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995; 91:2028-2035.
72. Rothman A, Sklansky MS, Lucas VW, et al. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 1999; 84:682-686.
73. Law MA, Grifka RG, Mullins CE, et al. Atrial septostomy improves survival in select patients with pulmonary hypertension. Am Heart J 2007; 153:779-784.
74. Danon S, Levi DS, Alejos JC, et al. Reliable atrial septostomy by stenting of the atrial septum. Catheter Cardiovasc Interv 2005; 66:408-413.
75. Lammers AE, Derrick G, Haworth SG, et al. Efficacy and long-term patency of fenestrated amplatzer devices in children. Catheter Cardiovasc Interv 2007; 70:578-584.
76. Althoff TF, Knebel F, Panda A, et al. Long-term follow-up of a fenestrated Amplatzer atrial septal occluder in pulmonary arterial hypertension. Chest 2008; 133:283-285.
77. Noyes BE, Kurland G, Orenstein DM. Lung and heart-lung transplantation in children. Pediatr Pulmonol 1997; 23:39-48.
78. Bridges ND, Clark BJ, Gaynor JW, et al. Outcome of children with pulmonary hypertension referred for lung or heart and lung transplantation. Transplantation 1996; 62:1824-1828.